Perry Capital Partners

Sharebite is a meal benefits platform designed for the modern workforce. Combining team orders, flexible solutions, centralized meal allowances, curated restaurant choices, and community impact, Sharebite helps the world's best companies elevate employee engagement. Sharebite's corporate clients include category-leading companies across financial services, tech, legal, consulting, entertainment, agency, real estate, and other verticals. Every transaction made on the Sharebite platform results in a donation to alleviate hunger in local communities via its partnerships with Feeding America and City Harvest.

Loadsmart helps shippers move their freight fast and Carriers keep trucks full. The company’s online platform enables users to get quotes, book trucks, and track their freight from pickup to delivery. Loadsmart was founded in 2014 by Felipe Capella and Ricardo Salgado and is based in Chicago, Illinois, United States.

Loadsmart helps shippers move their freight fast and Carriers keep trucks full. The company’s online platform enables users to get quotes, book trucks, and track their freight from pickup to delivery. Loadsmart was founded in 2014 by Felipe Capella and Ricardo Salgado and is based in Chicago, Illinois, United States.

Capital Factors is an innovative and leading provider of factoring, credit protection, accounts receivable collection services.

Palatin Technologies is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for treating diseases with significant unmet medical needs and commercial potential. Their programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Their primary product in clinical development is bremelanotide for treating female sexual dysfunction (FSD). In addition, they have drug candidates or development programs for obesity, erectile dysfunction, pulmonary diseases, cardiovascular diseases, and inflammatory diseases. Their current focus is on the design and development of receptor-selective melanocortin agonists for inflammation and autoimmune conditions, with a focus on ocular diseases. Their therapeutics work by activating endogenous melanocortin pathways to resolve damaging inflammation and allow affected tissues time to heal. Research has shown melanocortin agonists can prevent and reverse inflammation in disease models, including in the eyes and intestine—two of their targeted areas.